Structure-Guided Designed [¹⁸F]-labeled FAPI for Enhanced Hydrophilicity: From

[18F]AlF-NOTA-GL01 is a fibroblast activation protein (FAP)-targeting radiopharmaceutical for PET imaging. The dataset, shared by Xingyu Mu on figshare in 2026, contains results from preclinical evaluation and a first-in-human study, including metrics like binding affinity, hydrophilicity, tumor uptake, and effective dose. The file is a 372-byte CSV.

Use Cases

• Benchmarking new FAP-targeting tracers based on reported binding affinity (IC50 = 2.94 nM) and hydrophilicity (LogD = -3.06).
• Analyzing tumor uptake and clearance kinetics based on preclinical PET imaging results (7.45 ± 2.34%ID/g at 60 min).
• Estimating radiation dosimetry for clinical translation based on the reported effective dose (0.03 ± 0.01 mSv/MBq).
• Comparing imaging contrast against other tracers like [18F]FDG and [18F]FAPI-42 based on target-to-background ratios mentioned in the human study.

Strengths

• Includes specific, quantitative preclinical results: high radiochemical purity (>95%), FAP binding affinity (IC50 = 2.94 nM), and hydrophilicity (LogD = -3.06).
• Reports first-in-human study outcomes, including tumor uptake persistence and comparative target-to-background ratios against established tracers.
• Provides a clear radiation dose estimate (0.03 ± 0.01 mSv/MBq) relevant for clinical safety assessment.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The dataset is extremely small (372 bytes), indicating it likely contains only summary statistics, not raw imaging or individual subject data.

Provenance

Source

Xingyu Mu via figshare.

Collection Method

Data appears to be derived from a structure-guided design, preclinical evaluation in A549-hFAP xenografts, and a first-in-human PET/CT study.

Freshness

Last updated 2026-05-29 09:13:27; freshness should be verified.